European Heart Journal Advance Access originally published online on November 17, 2005
European Heart Journal 2006 27(3):330-337; doi:10.1093/eurheartj/ehi631
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients
The International Collaborative of NT-proBNP Study
1Cardiology Division, Massachusetts General Hospital, Yawkey 5984, 55 Fruit Street, Boston, MA 02114, USA
2Cardiology Department, University Hospital, Maastricht, The Netherlands
3Christchurch Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
4Cardiology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
5Biochemistry Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
6Emergency Medicine, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Received 5 July 2005; revised 14 September 2005; accepted 13 October 2005; online publish-ahead-of-print 17 November 2005.
* Corresponding author. Tel: +1 617 726 3443; fax: +1 617 643 1620. E-mail address: jjanuzzi{at}partners.org
Aims Experience with amino-terminal pro-brain natriuretic peptide (NT-proBNP) testing for evaluation of dyspnoeic patients with suspected acute heart failure (HF) is limited to single-centre studies. We wished to establish broader standards for NT-proBNP testing in a study involving four sites in three continents.
Methods and results Differences in NT-proBNP levels among 1256 patients with and without acute HF and the relationship between NT-proBNP levels and HF symptoms were examined. Optimal cut-points for diagnosis and prognosis were identified and verified using bootstrapping and multi-variable logistic regression techniques. Seven hundred and twenty subjects (57.3%) had acute HF, whose median NT-proBNP was considerably higher than those without (4639 vs. 108 pg/mL, P<0.001), and levels of NT-proBNP correlated with HF symptom severity (P=0.008). An optimal strategy to identify acute HF was to use age-related cut-points of 450, 900, and 1800 pg/mL for ages <50, 50–75, and >75, which yielded 90% sensitivity and 84% specificity for acute HF. An age-independent cut-point of 300 pg/mL had 98% negative predictive value to exclude acute HF. Among those with acute HF, a presenting NT-proBNP concentration >5180 pg/mL was strongly predictive of death by 76 days [odds ratio=5.2, 95% confidence interval (CI)=2.2–8.1, P<0.001].
Conclusion In this multi-centre, international study, NT-proBNP testing was valuable for diagnostic evaluation and short-term prognosis estimation in dyspnoeic subjects with suspected or confirmed acute HF and should establish broader standards for use of the NT-proBNP in dyspnoeic patients.
Key Words: Natriuretic peptides • Diagnosis • Prognosis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y Allanore, K Wahbi, D Borderie, S Weber, A Kahan, and C Meune N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment? Ann Rheum Dis, December 1, 2009; 68(12): 1885 - 1889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. V. Shah, A. A. Chen-Tournoux, M. H. Picard, R. R.J. van Kimmenade, and J. L. Januzzi Serum Levels of the Interleukin-1 Receptor Family Member ST2, Cardiac Structure and Function, and Long-Term Mortality in Patients With Acute Dyspnea Circ Heart Fail, July 1, 2009; 2(4): 311 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Shah, W. J. Kop, R. H. Christenson, D. B. Diercks, D. Kuo, S. Henderson, K. Hanson, S.-Y. Li, and C. R. deFilippi Natriuretic peptides and echocardiography in acute dyspnoea: implication of elevated levels with normal systolic function Eur J Heart Fail, July 1, 2009; 11(7): 659 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. deFilippi and R. H. Christenson B-Type Natriuretic Peptide (BNP)/NT-proBNP and Renal Function: Is the Controversy Over? Clin. Chem., July 1, 2009; 55(7): 1271 - 1273. [Full Text] [PDF]
|
|
|
|
|
|
S. C. Palmer, Z. H. Endre, A. M. Richards, and T. G. Yandle Characterization of NT-proBNP in Human Urine Clin. Chem., June 1, 2009; 55(6): 1126 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Alehagen, U. Dahlstrom, and T. L. Lindahl Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care Eur J Heart Fail, April 1, 2009; 11(4): 354 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gheorghiade and P. S. Pang Acute heart failure syndromes. J. Am. Coll. Cardiol., February 17, 2009; 53(7): 557 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Troughton and A. M. Richards B-type natriuretic peptides and echocardiographic measures of cardiac structure and function. J. Am. Coll. Cardiol. Img., February 1, 2009; 2(2): 216 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Hawkins, M. C. Petrie, P. S. Jhund, G. W. Chalmers, F. G. Dunn, and J. J.V. McMurray Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology Eur J Heart Fail, February 1, 2009; 11(2): 130 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C Kelder, F. H Rutten, and A. W Hoes Clinically relevant diagnostic research in primary care: the example of B-type natriuretic peptides in the detection of heart failure Fam. Pract., February 1, 2009; 26(1): 69 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. L. Pina and C. O'Connor BNP-Guided Therapy for Heart Failure JAMA, January 28, 2009; 301(4): 432 - 434. [Full Text] [PDF]
|
|
|
|
|
|
K. B. Shah, W. J. Kop, R. H. Christenson, D. B. Diercks, D. Kuo, S. Henderson, K. Hanson, M. R. Mehra, and C. R. deFilippi Lack of Diagnostic and Prognostic Utility of Circulating Plasma Myeloperoxidase Concentrations in Patients Presenting with Dyspnea Clin. Chem., January 1, 2009; 55(1): 59 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. L. Miller, K. A. Hartman, D. E. Grill, J. C. Burnett Jr, and A. S. Jaffe Only Large Reductions in Concentrations of Natriuretic Peptides (BNP and NT-proBNP) Are Associated with Improved Outcome in Ambulatory Patients with Chronic Heart Failure Clin. Chem., January 1, 2009; 55(1): 78 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ray, S. Delerme, P. Jourdain, and C. Chenevier-Gobeaux Differential diagnosis of acute dyspnea: the value of B natriuretic peptides in the emergency department QJM, November 1, 2008; 101(11): 831 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Olshansky, H. N. Sabbah, P. J. Hauptman, and W. S. Colucci Parasympathetic Nervous System and Heart Failure: Pathophysiology and Potential Implications for Therapy Circulation, August 19, 2008; 118(8): 863 - 871. [Full Text] [PDF]
|
|
|
|
|
|
A. S. Maisel, W. F. Peacock, N. McMullin, R. Jessie, G. C. Fonarow, J. Wynne, and R. M. Mills Timing of Immunoreactive B-Type Natriuretic Peptide Levels and Treatment Delay in Acute Decompensated Heart Failure: An ADHERE (Acute Decompensated Heart Failure National Registry) Analysis J. Am. Coll. Cardiol., August 12, 2008; 52(7): 534 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Daniels, G. A. Laughlin, P. Clopton, A. S. Maisel, and E. Barrett-Connor Minimally Elevated Cardiac Troponin T and Elevated N-Terminal Pro-B-Type Natriuretic Peptide Predict Mortality in Older Adults: Results From the Rancho Bernardo Study J. Am. Coll. Cardiol., August 5, 2008; 52(6): 450 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A L Baggish, D M Lloyd-Jones, J Blatt, A M Richards, J Lainchbury, M O'Donoghue, R Sakhuja, A A Chen, and J L Januzzi A clinical and biochemical score for mortality prediction in patients with acute dyspnoea: derivation, validation and incorporation into a bedside programme Heart, August 1, 2008; 94(8): 1032 - 1037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C H J Michielsen, J. A Bakker, R. R J V. Kimmenade, Y. M Pinto, and M. P V. Dieijen-Visser The diagnostic value of serum and urinary NT-proBNP for heart failure Ann Clin Biochem, July 1, 2008; 45(4): 389 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Januzzi Jr Use of Biomarkers to Predict Cardiac Risk from Medications: Getting to the Heart of the Matter Clin. Chem., July 1, 2008; 54(7): 1107 - 1109. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Green, A. Martinez-Rumayor, S. A. Gregory, A. L. Baggish, M. L. O'Donoghue, J. A. Green, K. B. Lewandrowski, and J. L. Januzzi Jr Clinical Uncertainty, Diagnostic Accuracy, and Outcomes in Emergency Department Patients Presenting With Dyspnea Arch Intern Med, April 14, 2008; 168(7): 741 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Alehagen and M. Janzon A clinician's experience of using the Cardiac Reader NT-proBNP point-of-care assay in a clinical setting Eur J Heart Fail, March 1, 2008; 10(3): 260 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Zannad, W. G. Stough, B. Pitt, J. G.F. Cleland, K. F. Adams, N. L. Geller, C. Torp-Pedersen, B.-A. Kirwan, and F. Follath Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition Eur. Heart J., February 1, 2008; 29(3): 413 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Perik, B. Rikhof, F. A. de Jong, J. Verweij, J. A. Gietema, and W. T. A. van der Graaf Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity Ann. Onc., February 1, 2008; 19(2): 359 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Daniels and A. S. Maisel Natriuretic Peptides J. Am. Coll. Cardiol., December 18, 2007; 50(25): 2357 - 2368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. De Ferrari, A. Sanzo, A. Bertoletti, G. Specchia, E. Vanoli, and P. J. Schwartz Baroreflex Sensitivity Predicts Long-Term Cardiovascular Mortality After Myocardial Infarction Even in Patients With Preserved Left Ventricular Function J. Am. Coll. Cardiol., December 11, 2007; 50(24): 2285 - 2290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Mueller B-Type Natriuretic Peptides and the General Practitioner J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1702 - 1703. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Swedberg Pure heart rate reduction: further perspectives in heart failure Eur. Heart J. Suppl., September 1, 2007; 9(suppl_F): F20 - F24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lassus, V.-P. Harjola, R. Sund, K. Siirila-Waris, J. Melin, K. Peuhkurinen, K. Pulkki, M. S. Nieminen, and for the FINN-AKVA Study group Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP Eur. Heart J., August 1, 2007; 28(15): 1841 - 1847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Metra, S. Nodari, G. Parrinello, C. Specchia, L. Brentana, P. Rocca, F. Fracassi, T. Bordonali, P. Milani, R. Danesi, et al. The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T Eur J Heart Fail, August 1, 2007; 9(8): 776 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hogenhuis, A. A. Voors, T. Jaarsma, A. W. Hoes, H. L. Hillege, J. A. Kragten, and D. J. van Veldhuisen Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure Eur J Heart Fail, August 1, 2007; 9(8): 787 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure Circulation, July 31, 2007; 116(5): e99 - e109. [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Richards Natriuretic Peptides: Update on Peptide Release, Bioactivity, and Clinical Use Hypertension, July 1, 2007; 50(1): 25 - 30. [Full Text] [PDF]
|
|
|
|
|
|
G. W. Moe, J. Howlett, J. L. Januzzi, H. Zowall, and for the Canadian Multicenter Improved Management o N-Terminal Pro-B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure: Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE-CHF Study Circulation, June 19, 2007; 115(24): 3103 - 3110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Rutten, M.-J. M. Cramer, N. P.A. Zuithoff, J.-W. J. Lammers, W. Verweij, D. E. Grobbee, and A. W. Hoes Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease Eur J Heart Fail, June 1, 2007; 9(6-7): 651 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Fonarow, W. F. Peacock, C. O. Phillips, M. M. Givertz, M. Lopatin, and for the ADHERE Scientific Advisory Committee and I Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure J. Am. Coll. Cardiol., May 15, 2007; 49(19): 1943 - 1950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sakhuja, S. Green, E. M. Oestreicher, P. M. Sluss, E. Lee-Lewandrowski, K. B. Lewandrowski, and J. L. Januzzi Jr. Amino-Terminal Pro-Brain Natriuretic Peptide, Brain Natriuretic Peptide, and Troponin T for Prediction of Mortality in Acute Heart Failure Clin. Chem., March 1, 2007; 53(3): 412 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bayes-Genis, D. M. Lloyd-Jones, R. R. J. van Kimmenade, J. G. Lainchbury, A. M. Richards, J. Ordonez-Llanos, M. Santalo, Y. M. Pinto, and J. L. Januzzi Jr Effect of Body Mass Index on Diagnostic and Prognostic Usefulness of Amino-Terminal Pro-Brain Natriuretic Peptide in Patients With Acute Dyspnea Arch Intern Med, February 26, 2007; 167(4): 400 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. W. Eurlings, J. L. Januzzi, and Y. M. Pinto Is acute heart failure a highly prevalent orphan disease? Eur. Heart J., November 2, 2006; 27(22): 2619 - 2620. [Full Text] [PDF]
|
|
|
|
|
|
R. R.J. van Kimmenade, J. L. Januzzi Jr, A. L. Baggish, J. G. Lainchbury, A. Bayes-Genis, A. M. Richards, and Y. M. Pinto Amino-Terminal Pro-Brain Natriuretic Peptide, Renal Function, and Outcomes in Acute Heart Failure: Redefining the Cardiorenal Interaction? J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1621 - 1627. [Abstract] [Full Text] [PDF]
|
|